Drug intelligence / Profile preview

oseltidine

Development stage: Preclinical
Lead developer: Roche
Modality: Small Molecules
Administration: Intravenous

Overview

Oseltidine is an investigational pharmaceutical drug administered via intravenous injection for patient-controlled analgesia (PCA). It is being studied for its efficacy in managing pain following hip replacement surgery in elderly patients. In clinical trials, oseltidine is administered as a loading dose prior to surgery, followed by on-demand PCA with a specified dose and lockout interval, and is being compared against hydromorphone.

Other names: Fumarate Oseltidine Injection

Targets

Neuraminidase

Beyond the preview

Go deeper on oseltidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oseltidine.

Explore the full profile